Inovio Pharmaceuticals (NASDAQ:INO) Research Coverage Started at Stephens

Stephens initiated coverage on shares of Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) in a report issued on Tuesday, MarketBeat.com reports. The brokerage set an "overweight" rating and a $20.00 price target on the biopharmaceutical company's stock. Stephens' target price points to a potential upside of 75.13% from the stock's previous close.

INO has been the subject of a number of other reports. StockNews.com cut shares of Inovio Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Friday, April 5th. Royal Bank of Canada reiterated a "sector perform" rating on shares of Inovio Pharmaceuticals in a research report on Thursday, March 7th. Finally, Oppenheimer raised shares of Inovio Pharmaceuticals from a "market perform" rating to an "outperform" rating and set a $48.00 price target for the company in a research report on Thursday, January 25th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat, Inovio Pharmaceuticals has an average rating of "Hold" and an average price target of $70.67.

Inovio Pharmaceuticals Stock Performance

NASDAQ:INO traded up $0.06 during trading hours on Tuesday, reaching $11.42. The company's stock had a trading volume of 410,951 shares, compared to its average volume of 480,620. The company has a market capitalization of $266.89 million, a P/E ratio of -1.51 and a beta of 1.16. The stock has a 50 day moving average price of $11.30 and a two-hundred day moving average price of $36.97. Inovio Pharmaceuticals has a 12 month low of $3.89 and a 12 month high of $14.75.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last announced its earnings results on Monday, May 13th. The biopharmaceutical company reported ($1.31) EPS for the quarter, missing analysts' consensus estimates of ($1.08) by ($0.23). Inovio Pharmaceuticals had a negative return on equity of 79.86% and a negative net margin of 16,238.91%. During the same quarter in the prior year, the company earned ($1.92) earnings per share. As a group, analysts predict that Inovio Pharmaceuticals will post -4.09 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Vanguard Personalized Indexing Management LLC acquired a new stake in Inovio Pharmaceuticals in the 3rd quarter valued at $42,000. Prime Capital Investment Advisors LLC lifted its holdings in Inovio Pharmaceuticals by 213.5% during the third quarter. Prime Capital Investment Advisors LLC now owns 138,972 shares of the biopharmaceutical company's stock valued at $54,000 after purchasing an additional 94,637 shares in the last quarter. Pathstone Family Office LLC grew its position in shares of Inovio Pharmaceuticals by 344.2% in the third quarter. Pathstone Family Office LLC now owns 148,392 shares of the biopharmaceutical company's stock valued at $58,000 after purchasing an additional 114,989 shares during the period. Keystone Financial Group grew its position in shares of Inovio Pharmaceuticals by 11.7% in the fourth quarter. Keystone Financial Group now owns 122,737 shares of the biopharmaceutical company's stock valued at $63,000 after purchasing an additional 12,840 shares during the period. Finally, Acadian Asset Management LLC acquired a new position in shares of Inovio Pharmaceuticals during the 3rd quarter worth about $178,000. Institutional investors and hedge funds own 26.79% of the company's stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.